Gregory Norden

Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

Greatwide Logistics Services, Inc. provides transportation, truckload management, and logistics services. It offers labour, warehousing and transportation management solutions, reverse logistics, inventory visibility, key performance indicator and metrics reporting, food grade facilities, and cross-docking, import deconsolidation and merge in-transit operations. The company was founded in 1967 and is headquartered in Dallas, TX.

Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL.

Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ.

Univision Communications, Inc. provides television and radio network services. It operates a Spanish-language broadcast television network. The firm produces and delivers content across various media platforms to inform, entertain, and empower Hispanic America. The company was founded in 1961 and is headquartered in New York, NY.

Univision Holdings, Inc. operates as an investment holding company, which engages in the provision of media services. The company is headquartered in New York, NY.

RP Management LLC provides pharmaceutical royalty liquidity services. It provides liquidity to holders of interests in revenue-producing intellectual property in biopharmaceutical products and finances the clinical development of biopharmaceutical products in exchange for a royalty interest. The firm serves research institutions, inventors, and biotechnology and pharmaceutical companies. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA.

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.

Anthos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops and commercializes innovative therapies for high-risk cardiovascular patients. It offers MAA868, an antibody directed at Factor XI and XIa, key components of the intrinsic coagulation pathway. The company was founded by Paris Panayiotopoulos, Ari Brettman and Jonathan E. Freeman in 2018 and is headquartered in Cambridge, MA.